TY - JOUR
T1 - Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
AU - Conter, Valentino
AU - Valsecchi, Maria Grazia
AU - Parasole, Rosanna
AU - Putti, Maria Caterina
AU - Locatelli, Franco
AU - Barisone, Elena
AU - Nigro, Luca Lo
AU - Santoro, Nicola
AU - Aricò, Maurizio
AU - Ziino, Ottavio
AU - Pession, Andrea
AU - Testi, Anna Maria
AU - Micalizzi, Concetta
AU - Casale, Fiorina
AU - Zecca, Marco
AU - Casazza, Gabriella
AU - Tamaro, Paolo
AU - La Barba, Gaetano
AU - Notarangelo, Lucia Dora
AU - Silvestri, Daniela
AU - Colombini, Antonella
AU - Rizzari, Carmelo
AU - Biondi, Andrea
AU - Masera, Giuseppe
AU - Basso, Giuseppe
PY - 2014
Y1 - 2014
N2 - The outcome of high-risk (HR) acute lymphoblastic leukemia patients enrolled in the AIEOP-BFM ALL 2000 study in Italy is described. HR criteria were minimal residual disease (MRD) levels >= 10(-3) at day 78 (MRD-HR), no complete remission (CR) at day 33, t(4;11) translocation, and prednisone poor response(PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, and maintenance. A total of 312 HR patients had a 5-year event-free survival (EFS) of 58.9% (standard error [SE] = 2.8) and an overall survival of 68.9% (SE = 2.6). In hierarchical order, EFS was 45.9% (4.4) in 132 MRD-HR patients, 41.2% (11.9) in 17 patients with no CR at day 33, 36.4% (14.5) in 11 patients with t(4; 11), and 74.0% (3.6) in 152 HR patients only for PPR. No statistically significant difference was found for disease-free survival in patients with very HR features [MRD-HR, no CR at day 33, t(4; 11) translocation], given hematopoietic stem cell transplantation (HSCT) (n = 66) or chemotherapy only (n = 88), after adjusting for waiting time to HSCT (5.7 months). Patients at HR only for PPR have a favorable outcome. MRD-HR is associated with poor outcome despite intensive treatment and/or HSCT and may qualify for innovative therapies. The study was registered at www.clinicaltrials.gov as #NCT00613457.
AB - The outcome of high-risk (HR) acute lymphoblastic leukemia patients enrolled in the AIEOP-BFM ALL 2000 study in Italy is described. HR criteria were minimal residual disease (MRD) levels >= 10(-3) at day 78 (MRD-HR), no complete remission (CR) at day 33, t(4;11) translocation, and prednisone poor response(PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, and maintenance. A total of 312 HR patients had a 5-year event-free survival (EFS) of 58.9% (standard error [SE] = 2.8) and an overall survival of 68.9% (SE = 2.6). In hierarchical order, EFS was 45.9% (4.4) in 132 MRD-HR patients, 41.2% (11.9) in 17 patients with no CR at day 33, 36.4% (14.5) in 11 patients with t(4; 11), and 74.0% (3.6) in 152 HR patients only for PPR. No statistically significant difference was found for disease-free survival in patients with very HR features [MRD-HR, no CR at day 33, t(4; 11) translocation], given hematopoietic stem cell transplantation (HSCT) (n = 66) or chemotherapy only (n = 88), after adjusting for waiting time to HSCT (5.7 months). Patients at HR only for PPR have a favorable outcome. MRD-HR is associated with poor outcome despite intensive treatment and/or HSCT and may qualify for innovative therapies. The study was registered at www.clinicaltrials.gov as #NCT00613457.
KW - N/A
KW - N/A
UR - http://hdl.handle.net/10807/242502
U2 - 10.1182/blood-2013-10-532598
DO - 10.1182/blood-2013-10-532598
M3 - Article
SN - 1528-0020
VL - 123
SP - 1470
EP - 1478
JO - Blood
JF - Blood
ER -